These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 8135194

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Correction of protein binding defect in uremic sera by charcoal treatment.
    Craig WA, Evenson MA, Sarver KP, Wagnild JP.
    J Lab Clin Med; 1976 Apr; 87(4):637-47. PubMed ID: 1270877
    [Abstract] [Full Text] [Related]

  • 3. Carbamazepine-salicylate interaction in normal and uremic sera: reduced interaction in uremic sera.
    Dasgupta A, Thompson WC.
    Ther Drug Monit; 1995 Apr; 17(2):199-202. PubMed ID: 7624911
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Displacement of valproic acid and carbamazepine from protein binding in normal and uremic sera by tolmetin, ibuprofen, and naproxen: presence of inhibitor in uremic serum that blocks valproic acid-naproxen interactions.
    Dasgupta A, Volk A.
    Ther Drug Monit; 1996 Jun; 18(3):284-7. PubMed ID: 8738769
    [Abstract] [Full Text] [Related]

  • 7. Unexpected suppression of free phenytoin concentration by salicylate in uremic sera due to the presence of inhibitors: MALDI mass spectrometric determination of molecular weight range of inhibitors.
    Biddle DA, Wells A, Dasgupta A.
    Life Sci; 2000 Jun; 66(2):143-51. PubMed ID: 10666010
    [Abstract] [Full Text] [Related]

  • 8. Interaction of valproic acid with nonsteroidal antiinflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: lack of interaction in uremic sera due to the presence of endogenous factors.
    Dasgupta A, Emerson L.
    Ther Drug Monit; 1996 Dec; 18(6):654-9. PubMed ID: 8946661
    [Abstract] [Full Text] [Related]

  • 9. Uremic sera contain inhibitors that block digitoxin-valproic acid interaction.
    Dasgupta A, Paul A, Wells A.
    Am J Med Sci; 2001 Oct; 322(4):204-8. PubMed ID: 11678517
    [Abstract] [Full Text] [Related]

  • 10. [Valproic acid in the treatment of epilepsy with special emphasis on serum level determination (author's transl)].
    Fröscher W, Schulz HU, Gugler R.
    Fortschr Neurol Psychiatr Grenzgeb; 1978 Jun; 46(6):327-41. PubMed ID: 352872
    [Abstract] [Full Text] [Related]

  • 11. Drug interaction. Effects of salicylate on pharmacokinetics of valproic acid in rats.
    Yu HY, Shen YZ, Sugiyama Y, Hanano M.
    Drug Metab Dispos; 1990 Jun; 18(1):121-6. PubMed ID: 1970771
    [Abstract] [Full Text] [Related]

  • 12. Valproic acid-ketoconazole interaction in normal, hypoalbuminemic, and uremic sera: lack of interaction in uremic serum caused by the presence of inhibitor.
    Dasgupta A, Luke M.
    Ther Drug Monit; 1997 Jun; 19(3):281-5. PubMed ID: 9200768
    [Abstract] [Full Text] [Related]

  • 13. Effect of heparin or salicylate infusion on serum protein binding and on concentrations of phenytoin in serum, brain and cerebrospinal fluid of rats.
    Chou RC, Levy G.
    J Pharmacol Exp Ther; 1981 Oct; 219(1):42-8. PubMed ID: 7288614
    [Abstract] [Full Text] [Related]

  • 14. Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis. Role of uremic compounds.
    Dasgupta A, Abu-Alfa A.
    Am J Clin Pathol; 1992 Jul; 98(1):19-25. PubMed ID: 1615921
    [Abstract] [Full Text] [Related]

  • 15. Inability of accumulated metabolic byproducts of uremia to alter the extent of warfarin binding in charcoal treated plasma.
    Bachmann K, Conway P, Shapiro R.
    Res Commun Chem Pathol Pharmacol; 1978 Apr; 20(1):117-30. PubMed ID: 663394
    [Abstract] [Full Text] [Related]

  • 16. Serum protein binding of valproic acid in healthy subjects and in patients with liver disease.
    Urien S, Albengres E, Tillement JP.
    Int J Clin Pharmacol Ther Toxicol; 1981 Jul; 19(7):319-25. PubMed ID: 6790449
    [Abstract] [Full Text] [Related]

  • 17. Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin.
    Dasgupta A, Crossey MJ.
    Am J Med Sci; 1997 Feb; 313(2):75-9. PubMed ID: 9030671
    [Abstract] [Full Text] [Related]

  • 18. Elevated free fosphenytoin concentrations in uremic sera: uremic toxins hippuric acid and indoxyl sulfate do not account for the impaired protein binding of fosphenytoin.
    Dasgupta A, Havlik D.
    Ther Drug Monit; 1998 Dec; 20(6):658-62. PubMed ID: 9853983
    [Abstract] [Full Text] [Related]

  • 19. Factors affecting the serum protein binding of salicylic acid in newborn infants and their mothers.
    Hamar C, Levy G.
    Pediatr Pharmacol (New York); 1980 Dec; 1(1):31-43. PubMed ID: 7202184
    [Abstract] [Full Text] [Related]

  • 20. Uricosuric agents in uremic sera. Identification of indoxyl sulfata and hippuric acid.
    Boumendil-Podevin EF, Podevin RA, Richet G.
    J Clin Invest; 1975 Jun; 55(6):1142-52. PubMed ID: 1133164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.